Curacle Co., Ltd.

Korea Advanced Institute of Science and Technology

Gwangju Institute of Science and Technology

Kyungpook National University Industry-academic Cooperation Foundation

Yonsei University

Jung-In Pyo

Young-Guen Kwon

Myung-Hwa Kim

Jae-Han Jeon

In-Kyu Lee

Jin Hee Ahn

Hail Kim

Chul Su Baek

Koo Hyeon Ahn

Haushabhau Shivaji Pagire

Ajin Lim

Haiying Zhang

Suvarna Haus-habhau Pagire

Ko Eun Shong

Eun Jung Bae

Kun-Young Park

Kwang-eun Kim

Jaemyoung Suh

Minyoung Noh

Songyi Park

Yeomyeong Kim

The present invention relates to a crystalline form of (E)-methyl 6-((3S,8S,9S,10R,13S,14S,17R)-3-(((5S,6R)-5-acetoxy-6-(acetoxytnethyl)-5,6-dihydro-2H-pyran-2-yl)oxy)-10,13-dimethyl-2,3,4,7,8,9,10.11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)hept-5-enoate and a blood vessel leak blocker comprising the same. The novel crystalline form has high purity, excellent stability, excellent long-term storage and pharmaceutical stability, and can be used as a vascular leakage blocker, so it is very advantageous in producing high-quality drug substances.

Crystalline form of vascular leakage blocker compound

The present invention relates to a novel tryptophan hydroxylase inhibitor and a pharmaceutical composition including same, wherein the novel tryptophan hydroxylase inhibitor has an excellent inhibitory effect on TPH1, and thus can be usefully used for the prevention or treatment of disorders, such as metabolic disorders, cancer, digestive or cardiovascular system disorders, related to TPH1 activity. In particular, the novel tryptophan hydroxylase inhibitor has an excellent treatment effect on inflammatory bowel disorders, and thus can be usefully used for the treatment of inflammatory bowel disorder.

Tryptophan hydroxylase inhibitor and pharmaceutical composition including same

Growing community of inventors

Seongnam-si, South Korea

Jung-In Pyo